Posted by Michael Wonder on 02 Dec 2025
Merck granted fast track designation by the US FDA for MK-2214 for the treatment of Alzheimer's disease
1 December 2025 - MK-2214, an investigational novel antibody targeting phosphorylated serine 413 (pS413) tau.
Two studies assessed the safety, tolerability and pharmacokinetics of a single ascending dose of MK-2214 in healthy volunteers, while a third assessed the safety, tolerability and pharmacokinetics of a multiple ascending dose regimen in individuals with mild cognitive impairment and mild to moderate Alzheimer’s disease.
